Cargando…

Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy

T-cell therapy using genetically engineered T cells modified with either T cell receptor or chi-meric antigen receptor holds great promise for cancer immunotherapy. The concerns about its toxicities still remain despite recent successes in clinical trials. Temporal and spatial control of the enginee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Yan-Bei, Sun, Shang-Jun, Han, Shuang-Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876919/ https://www.ncbi.nlm.nih.gov/pubmed/29283058 http://dx.doi.org/10.2174/1381612824666171227222624

Ejemplares similares

Genetically engineered T cells for cancer immunotherapy
por: Li, Dan, et al.
Publicado: (2019)

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
por: Han, Ethan Q, et al.
Publicado: (2013)

Editorial: Engineered Targeted Cancer Immunotherapies
por: Fantini, Massimo, et al.
Publicado: (2022)

Editorial: Translation of genetically engineered T cells in cancer immunotherapy
por: Voss, Ralf-Holger, et al.
Publicado: (2023)

Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy
por: Cheng, Qinzhen, et al.
Publicado: (2023)

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
por: Tian, Yaomei, et al.
Publicado: (2022)

The prospect of genetically engineering natural killer cells for cancer immunotherapy
por: Poon, Angie Yu Ching, et al.
Publicado: (2022)

Nano-Optogenetic Engineering of CAR T-cells for Precision Immunotherapy with Enhanced Safety
por: Nguyen, Nhung Thi, et al.
Publicado: (2021)

Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy
por: Zhang, Tingting, et al.
Publicado: (2022)

Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
por: Jhawar, Sachin R., et al.
Publicado: (2017)

Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
por: Wu, Aihua, et al.
Publicado: (2021)

Advances in Engineering Cells for Cancer Immunotherapy
por: Xu, Xiao, et al.
Publicado: (2019)

Novel strategies for cancer immunotherapy: counter-immunoediting therapy
por: Liu, Shaochuan, et al.
Publicado: (2023)

Immunotherapy Strategies Against Multiple Myeloma
por: Ma, Jing, et al.
Publicado: (2017)

New strategy for cancer immunotherapy: using live engineered bacteria for metabolic modulation
por: Li, Tong, et al.
Publicado: (2021)

Nanoengineered targeting strategy for cancer immunotherapy
por: Yin, Wei-min, et al.
Publicado: (2020)

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
por: Chuntova, Pavlina, et al.
Publicado: (2019)

New Immunotherapy Strategies in Breast Cancer
por: Yu, Lin-Yu, et al.
Publicado: (2017)

Engineered biomaterials for cancer immunotherapy
por: Cai, Lulu, et al.
Publicado: (2020)

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010)

Engineering light-controllable CAR T cells for cancer immunotherapy
por: Huang, Ziliang, et al.
Publicado: (2020)

Engineering cGAS-agonistic oligonucleotides as therapeutics and vaccine adjuvants for cancer immunotherapy
por: Zhou, Shurong, et al.
Publicado: (2023)

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Strategies to sensitize cancer cells to immunotherapy
por: George, Andrew, et al.
Publicado: (2021)

Strategies for Manipulating T Cells in Cancer Immunotherapy
por: Lee, Hyang-Mi
Publicado: (2022)

Engineering dendritic cell vaccines to improve cancer immunotherapy
por: Perez, Caleb R., et al.
Publicado: (2019)

Functional bionanomaterials for cell surface engineering in cancer immunotherapy
por: Ma, Sheng, et al.
Publicado: (2021)

Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
por: Zhou, Yang, et al.
Publicado: (2022)

Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
por: Martin, Francisco, et al.
Publicado: (2022)

Synthetic Biology Technologies And Genetically Engineering Strategies For Enhanced Cell Therapeutics
por: Li, Siyu, et al.
Publicado: (2022)

Engineering neoantigen vaccines to improve cancer personalized immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2022)

In situ genetic engineering of tumors for long-lasting and systemic immunotherapy
por: Tzeng, Stephany Y., et al.
Publicado: (2020)

Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
por: Gao, Jing, et al.
Publicado: (2020)

Engineering Prodrug Nanomedicine for Cancer Immunotherapy
por: Yang, Bin, et al.
Publicado: (2020)

Genetic Modification of T Cells for the Immunotherapy of Cancer
por: Quinn, Suzanne, et al.
Publicado: (2022)

Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists
por: Jeong, Sehwan, et al.
Publicado: (2021)

T Cell Based Immunotherapy for Cancer: Approaches and Strategies
por: Want, Muzamil Y., et al.
Publicado: (2023)

Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies
por: Dong, Yan, et al.
Publicado: (2021)

Ultrasound-controllable engineered bacteria for cancer immunotherapy
por: Abedi, Mohamad H., et al.
Publicado: (2022)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a60trm6gj4vgv333kbn0b1debb